Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cidofovir 1% for high-grade anal intraepithelial neoplasia in HIV-positive patients
2012-001612-34Phase 2Completed
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cidofovir in anal intraepithelial neoplasia (AIN) and human immunodeficiency virus infection (HIV), sponsored by Fundación SEIMC-GeSIDA. Primary endpoints: Clinical and histological regression of anal intraepithelial neoplasia and Complete regression of anal intraepithelial neoplasia. Started Apr 2012; status: completed.
02
Drugs
cidofovir
03
Conditions
anal intraepithelial neoplasia (AIN)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2012-001612-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001612-34.